Noninferiority trial comparing a first-generation cephalosporin with a third-generation cephalosporin in the treatment of nonsevere clinical mastitis in dairy cows

Y. H. Schukken*, M. J. Zurakowski, B. J. Rauch, B. Gross, L. L. Tikofsky, F. L. Welcome

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The objective of this study was to evaluate the noninferiority of 2 intramammary treatments for nonsevere clinical mastitis. The 2 treatments were a first-generation cephalosporin (cephapirin sodium, 2 treatments 12. h apart) and a third-generation cephalosporin (ceftiofur hydrochloride, treatments once a day for 5. d). A total of 296 cases on 7 farms met the enrollment criteria for the study. Streptococcus dysgalactiae was the most common bacterial species identified in milk samples from cows with mild to moderate clinical mastitis, followed by Escherichia coli, other esculin-positive cocci, Streptococcus uberis, and Klebsiella spp. Treatment was randomly allocated as either cephapirin sodium or ceftiofur hydrochloride via intramammary infusion according to label standards. Bacteriological cure was defined based on 2 posttreatment milk samples taken at 10 and 17. d after enrollment. Noninferiority of cephapirin relative to ceftiofur was shown for bacteriological cure of gram-positive cases and for clinical cure of all cases. Ceftiofur showed a significantly higher bacteriological cure in gram-negative cases. Treatments showed no significant difference in bacteriological cure of all cases and in time to exit from the study, where the absence of a difference does not imply noninferiority. Based on the findings from this study, farm-specific treatment protocols that differ for gram-positive and gram-negative cased may be developed.

Original languageEnglish
Pages (from-to)6763-6774
Number of pages12
JournalJournal of Dairy Science
Volume96
Issue number10
Early online date19 Aug 2013
DOIs
Publication statusPublished - Oct 2013
Externally publishedYes

Bibliographical note

Funding Information:
We acknowledge the support of the New York State dairy farmers participating in this study. We acknowledge Boehringer Ingelheim Vetmedica Inc. (St. Joseph, MO) for providing financial support of this study.

Funding

We acknowledge the support of the New York State dairy farmers participating in this study. We acknowledge Boehringer Ingelheim Vetmedica Inc. (St. Joseph, MO) for providing financial support of this study.

Keywords

  • Cephapirin
  • Clinical trial
  • Mastitis
  • Noninferiority

Fingerprint

Dive into the research topics of 'Noninferiority trial comparing a first-generation cephalosporin with a third-generation cephalosporin in the treatment of nonsevere clinical mastitis in dairy cows'. Together they form a unique fingerprint.

Cite this